Big Pharma's $18.3B Secret: Why U.S. Drug Giants Are Flooding China With Licensing Deals
U.S. pharma is turning east. Fast. Through June, American drugmakers have inked 14 licensing deals with China-based biotechspotentially worth $18.3 billion. That's not a typo: up from just two a year ago. The logic? Rebuild pipelines before $200 billion worth of current drugs lose patent protection. Pfizer (NYSE:PFE) paid $1.25 billion upfront for a cancer drug from China's 3SBio in May, in a deal that could balloon to $6 billion. Regeneron (NASDAQ:REGN) followed with an $80 million obesity drug deal from Hansoh Pharmaceuticals. Licensing gives U.S. firms faster, cheaper access to promising therapieswithout bearing the full cost of R&D. That's proving too good to ignore.
Warning! GuruFocus has detected 6 Warning Signs with PFE.
What's changed? Chinese biotech isn't just catching upit's producing world-class assets. Targeted therapies, first-in-class cancer drugs, and obesity treatments are all coming out of labs in Shanghai and Suzhou. Jefferies notes a shift away from traditional small molecules toward cutting-edge biologics. And the price? Still a bargain. Over the past five years, licensing deals in the U.S. have averaged $84.8 billion. In China? Just $31.3 billion. Even with U.S.China tensions running high, these intellectual property deals are exempt from tariffs. As Stifel's Tim Opler points out, The law applies to goods. It explicitly excludes IP.
Don't expect this to slow down. Roughly one-third of all licensed assets in 2024 so far have come from Chinaand analysts think that could hit 50% soon. Nuvation Bio (NYSE:NUVB) just acquired AnHeart Therapeutics for its China-developed cancer drug taletrectinib, approved in the U.S. last week. Deals like this don't just cut coststhey accelerate go-to-market. It's a wakeup call, says Chen Yu of TCGX. U.S. pharma isn't just buying molecules. It's buying time. And China's biotech engine might be the fastest route to the next blockbuster.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
A Look At The Intrinsic Value Of Spectral AI, Inc. (NASDAQ:MDAI)
Using the 2 Stage Free Cash Flow to Equity, Spectral AI fair value estimate is US$2.30 Current share price of US$2.19 suggests Spectral AI is potentially trading close to its fair value Our fair value estimate is 52% lower than Spectral AI's analyst price target of US$4.79 Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Spectral AI, Inc. (NASDAQ:MDAI) as an investment opportunity by estimating the company's future cash flows and discounting them to their present value. We will take advantage of the Discounted Cash Flow (DCF) model for this purpose. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine. We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. For those who are keen learners of equity analysis, the Simply Wall St analysis model here may be something of interest to you. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value: 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 Levered FCF ($, Millions) -US$8.90m -US$1.80m US$3.70m US$2.90m US$3.30m US$3.60m US$3.87m US$4.10m US$4.31m US$4.50m Growth Rate Estimate Source Analyst x1 Analyst x1 Analyst x1 Analyst x1 Analyst x1 Est @ 9.20% Est @ 7.32% Est @ 6.01% Est @ 5.09% Est @ 4.44% Present Value ($, Millions) Discounted @ 7.4% -US$8.3 -US$1.6 US$3.0 US$2.2 US$2.3 US$2.3 US$2.3 US$2.3 US$2.3 US$2.2 ("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = US$9.1m We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.9%. We discount the terminal cash flows to today's value at a cost of equity of 7.4%. Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = US$4.5m× (1 + 2.9%) ÷ (7.4%– 2.9%) = US$103m Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$103m÷ ( 1 + 7.4%)10= US$50m The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is US$59m. In the final step we divide the equity value by the number of shares outstanding. Compared to the current share price of US$2.2, the company appears about fair value at a 4.9% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent. We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Spectral AI as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.4%, which is based on a levered beta of 1.040. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. View our latest analysis for Spectral AI Strength Debt is well covered by earnings. Weakness Shareholders have been diluted in the past year. Opportunity Forecast to reduce losses next year. Current share price is below our estimate of fair value. Threat Debt is not well covered by operating cash flow. Has less than 3 years of cash runway based on current free cash flow. Total liabilities exceed total assets, which raises the risk of financial distress. Not expected to become profitable over the next 3 years. Valuation is only one side of the coin in terms of building your investment thesis, and it is only one of many factors that you need to assess for a company. The DCF model is not a perfect stock valuation tool. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. For Spectral AI, we've put together three essential factors you should further research: Risks: Take risks, for example - Spectral AI has 4 warning signs (and 2 which make us uncomfortable) we think you should know about. Future Earnings: How does MDAI's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing! PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the NASDAQCM every day. If you want to find the calculation for other stocks just search here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Business Insider
37 minutes ago
- Business Insider
Nisource (NI) Gets a Buy from BMO Capital
In a report released on June 18, James Thalacker from BMO Capital maintained a Buy rating on Nisource (NI – Research Report), with a price target of $44.00. The company's shares closed last Friday at $39.52. Confident Investing Starts Here: Thalacker covers the Utilities sector, focusing on stocks such as American Electric Power, Centerpoint Energy, and CMS Energy. According to TipRanks, Thalacker has an average return of 13.4% and a 64.52% success rate on recommended stocks. In addition to BMO Capital, Nisource also received a Buy from Jefferies's Julien Dumoulin Smith in a report issued on June 10. However, on June 3, Citi assigned a Hold rating to Nisource (NYSE: NI). NI market cap is currently $18.6B and has a P/E ratio of 21.29. Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NI in relation to earlier this year. Earlier this month, Melanie B. Berman, the EVP Administration & CHRO of NI sold 6,227.00 shares for a total of $245,468.34.
Boston Globe
42 minutes ago
- Boston Globe
Here's how Iran could retaliate after US strikes on its nuclear program
Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Ever since Israel started the war with a surprise bombardment of Iran's military and nuclear sites on June 13, Iranian officials from the supreme leader on down have warned the U.S. to stay out, saying it would have dire consequences for the entire region. Advertisement It should soon be clear whether those were empty threats or a grim forecast. Here's a look at what Iran's next move might be. Targeting the Strait of Hormuz The Strait of Hormuz is the narrow mouth of the Persian Gulf, through which some 20% of all oil traded globally passes, and at its narrowest point it is just 33 kilometers (21 miles) wide. Any disruption there could send oil prices soaring worldwide and hit American pocketbooks. Advertisement Iran boasts a fleet of fast-attack boats and thousands of naval mines that could potentially make the strait impassable, at least for a time. It could also fire missiles from its long Persian Gulf shore, as its allies, Yemen's Houthi rebels, have done in the Red Sea. The U.S., with its 5th Fleet stationed in nearby Bahrain, has long pledged to uphold freedom of navigation in the strait and would respond with far superior forces. But even a relatively brief firefight could paralyze shipping traffic and spook investors, causing oil prices to spike and generating international pressure for a ceasefire. Attacking US bases and allies in the region The U.S. has tens of thousands of troops stationed in the region, including at permanent bases in Kuwait, Bahrain, Qatar and the United Arab Emirates, Arab Gulf countries just across the Persian Gulf from Iran — and much closer than Israel. Those bases boast the same kinds of sophisticated air defenses as Israel, but would have much less warning time before waves of missiles or swarms of armed drones. And even Israel, which is several hundred kilometers (miles) further away, has been unable to stop all of the incoming fire. Iran could also choose to attack key oil and gas facilities in those countries with the goal of exacting a higher price for U.S. involvement in the war. A drone attack on two major oil sites in Saudi Arabia in 2019 — claimed by the Houthis but widely blamed on Iran — briefly cut the kingdom's oil production in half. Activating regional allies Iran's so-called Axis of Resistance — a network of militant groups across the Middle East, is a shadow of what it was before the war ignited by Hamas' Oct. 7, 2023, attack on Israel out of the Gaza Strip — but it still has some formidable capabilities. Advertisement Israel's 20-month war in Gaza has severely diminished the Palestinian Hamas and Islamic Jihad groups, and Israel mauled Lebanon's Hezbollah last fall, killing most of its top leadership and devastating much of southern Lebanon, making its involvement unlikely. But Iran could still call on the Houthis, who had threatened to resume their attacks in the Red Sea if the U.S. entered the war, and allied militias in Iraq. Both have drone and missile capabilities that would allow them to target the United States and its allies. Iran could also seek to respond through militant attacks further afield, as it is widely accused of doing in the 1990s with an attack on a Jewish community center in Argentina that was blamed on Tehran and Hezbollah. A sprint toward nuclear arms It could be days or weeks before the full impact of the U.S. strikes on Iran's nuclear sites is known. But experts have long warned that even joint U.S. and Israeli strikes would only delay Iran's ability to develop a weapon, not eliminate it. That's because Iran has dispersed its program across the country to several sites, including hardened, underground facilities. Iran would likely struggle to repair or reconstitute its nuclear program while Israeli and U.S. warplanes are circling overhead. But it could still decide to fully end its cooperation with the International Atomic Energy Agency and abandon the the Nuclear Nonproliferation Treaty. North Korea announced its withdrawal from the treaty in 2003 and tested a nuclear weapon three years later, but it had the freedom to develop its program without punishing airstrikes. Advertisement Iran insists its program is peaceful, though it is the only non-nuclear-armed state to enrich uranium up to 60%, a short, technical step away from weapons-grade levels of 90%. U.S. intelligence agencies and the IAEA assess Iran hasn't had an organized military nuclear program since 2003. Israel is widely believed to be the only nuclear-armed state in the Middle East but does not acknowledge having such weapons. Gambrell reported from Dubai, United Arab Emirates.
